And with that, I might now like to show the decision over to Joseph C. Papa. Joe?
Joseph C. Papa: Thanks, Frank, and good day, everybody. Welcome to Emergent’s third quarter 2025 Earnings Name. That is Joseph C. Papa, CEO of Emergent, and I am joined at present by Richard S. Lindahl, our Chief Monetary Officer. We’ll begin by offering third quarter highlights after which Wealthy will overview the third quarter financials. I will return to overview key enterprise catalysts to drive development. We’ll shut with a Q&A session. Turning to Slide 5, the Emergent workforce’s aspiration is to be the chief in fixing public well being crises all over the world. As a part of our mission to guard and save lives, we develop and ship extremely advanced merchandise to deal with a number of the world’s most urgent threats.
Based mostly on the efforts of our workforce, we had one other nice quarter and are on monitor to exceed our preliminary 2025 income and adjusted EBITDA steering. Yr thus far, we’ve got secured 11 contract modifications and product orders for our Biodefense enterprise whereas sustaining our market management place within the nasal naloxone class. We’ve got a sturdy Biodefense Enterprise Mannequin with a North America-based provide chain for our product and manufacturing within the US or within the USMCA compliant facility. Lastly, we consider our differentiated capabilities in plasma and hard-to-manufacture merchandise place us to be a strategic long-term associate for our clients. Turning to Slide six, Emergent was based 25 years in the past, and our enterprise is in contrast to conventional pharmaceutical corporations.
In truth, we’ve got essentially the most diversified biodefense and naloxone product portfolio. It’s centered on addressing the worldwide public well being threats of smallpox, anthrax, ten pox, Ebola, botulism, and even opioid overdose emergency conditions. Simply yesterday, we launched a brand new survey discovering that strengthened bioterrorism stays a big concern to knowledgeable public coverage leaders. Turning to slip eight, we’re making nice progress with our multi-year transformation. Throughout 2025, we proceed to make strategic investments for long-term development whereas creating vital worth for our stakeholders. We’re attaining working margin enhancements and validating greatest choices to advance top-line development whereas sustaining our engaging value construction.
On Slide 9, we offer a extra detailed take a look at the third quarter, together with exceeding our inside steering on each the highest and backside line. Third quarter revenues of $231 million have been $21 million above the excessive finish of our Q3 steering vary of $180 million to $210 million. Our profitability continues to enhance, and 12 months thus far, we’ve got already achieved the excessive finish of our full-year adjusted EBITDA steering vary of $194 million generated as of the third quarter. Each the income and profitability of the enterprise exceeded our inside administration expectations and the analyst consensus.
Based mostly on the year-to-date efficiency, we’re rising our adjusted EBITDA steering vary to $195 million to $210 million, up from $175 million to $200 million. Our liquidity stays very robust. We now have entry to $346 million in monetary capability to put money into extra development and capital deployment. This contains $246 million of steadiness sheet money and our undrawn revolver. We’re happy with the numerous assortment of money for accounts receivable even in the course of the first day in This autumn. We’re selectively deploying our capital to create stakeholder worth. Our internet leverage improved to roughly 2x internet debt to adjusted EBITDA, down from 3.3 instances in 2024. In 2025, we have additionally repurchased some Emergent bonds.
It continues with our share repurchase program the place we count on $15.8 million of our $50 million twelve-month program. We’re excited in regards to the progress within the NCM section with 4 new contract modifications added within the third quarter. We additionally see upside from our worldwide clients, which characterize 34% of our MCM gross sales 12 months thus far, which is up from the mid to excessive teenagers in previous years. Our management in Naloxone stays robust, and we’re dedicated as ever to fight the opioid overdose epidemic and saving lives. With two months left within the 12 months, we really feel superb about our 2025 efficiency and are actively working to determine extra development drivers for 2026 and past.
On Slide 10, we summarize the robust efficiency of our Naloxone enterprise 12 months thus far. We stay the chief within the naloxone class amongst public curiosity clients. We’re benefiting from a stabilized U.S. pricing marketplace for naloxone. Quarter over quarter, NARCAN unit quantity grew by 13% and income grew by 9%. This sequential development reaffirms that we’ve got moved previous one-time first quarter occasions. In truth, NRPM demand stays robust. We count on continued development of all the market, which can present a tailwind to our enterprise. Now I would like to show the decision over to Wealthy to stroll by means of the third quarter financials.
Richard S. Lindahl: Thanks, Joe. Good afternoon, everybody. We recognize you becoming a member of the decision. We’re off to a powerful begin in 2025. Our third quarter income got here in at $231 million, exceeding the higher finish of our steering vary by $21 million, pushed by sequential development of NARCAN and the addition of 4 new contract modifications. Via the third quarter, we proceed to see year-over-year enhancements in each gross margin and adjusted EBITDA margin, highlighting the effectivity of our enterprise that delivered a 38% adjusted EBITDA margin this previous quarter. To additional spotlight our robust efficiency, internet earnings for the third quarter was $51 million. Yr-to-date internet earnings was $107 million, and year-to-date earnings per share was $1.89.
Yr-to-date efficiency has additionally exceeded our inside expectations. We’re elevating our complete income steering to a spread of $775 million to $835 million, a $5 million enchancment on the midpoint. And we’re rising our adjusted EBITDA steering to a spread of $195 million to $210 million, a $15 million enhance on the midpoint as in comparison with our prior forecast. The profitability and money technology of our firm has allowed us to concentrate on creating alternatives to generate extra shareholder worth. Within the third quarter, we deployed money in the direction of each fairness and debt, profiting from opportunistic pricing. Even with these actions, our money place and leverage ratio remained in a powerful and steady place.
Each of our enterprise segments outperformed within the quarter, and importantly, we noticed no disruption from exterior macro components that could be pressuring the remainder of biopharma. We proceed to play an important position as a trusted associate to each the U.S. Authorities and our worldwide companions, with rising demand for our medical countermeasures as nations prioritize preparedness and response capabilities. Please flip to Slide 12 to overview our third quarter financials. I will begin by noting that the prior 12 months comparisons absolutely replicate our restructuring actions from early 2024. Highlights of the quarter embrace complete revenues of $231 million. As a reminder, third quarter 2024 benefited from a partial quarter of non-divested revenues from RSTL and the Camden facility.
Adjusted EBITDA margin of 38%, a rise of 200 foundation factors versus the prior 12 months, underscoring our continued robust profitability with our environment friendly platform. Adjusted gross margin of 61% improved 200 foundation factors 12 months over 12 months, pushed by a extra favorable product combine, the growth of strategic international partnerships, and a leaner value construction stemming from our divestitures and restructuring initiatives. And eventually, working bills of $52 million have been $38 million decrease in comparison with the prior 12 months. Of observe, you’ll be able to see that our SG&A spend declined roughly 50% from LiveSolver. Extra third quarter income particulars will be discovered within the appendix. Turning to Slide 13, I will stroll by means of our efficiency for the primary 9 months of 2025.
Whole revenues have been $594 million, a decline in comparison with the prior 12 months, reflecting the divestitures, the J&J one-time settlement in 2024, and strategic pricing actions taken on NARCAN. Adjusted EBITDA was $194 million or 33% of complete revenues, an enchancment of roughly $32 million and 1,400 foundation factors 12 months over 12 months. This consequence illustrates our robust working leverage, the influence of our restructuring actions, in addition to a positive product combine in 2025 pushed by worldwide MCM gross sales. Adjusted gross margin of 57% improved 1,100 factors in comparison with the prior 12 months. This growth was pushed by product combine and continued operational efficiencies stemming from the 2024 initiatives. Working bills totaled $176 million, a $133 million discount from the prior 12 months.
Most of this discount got here from a $112 million decline in SG&Some time we preserved crucial R&D capabilities to help long-term development. Shifting on to Slide 14. For the primary 9 months of 2025, complete income was $594 million, pushed by complete product gross sales of $545 million. As famous, 2024 contains income related to one-time occasions and property. The desk within the higher proper nook of Slide 14 normalizes 2024 income for these things. With that, let’s break down efficiency by key product strains. Naloxone nasal spray income totaled $188 million, reflecting improved sequential momentum from the second and third quarters. Anthrax medical countermeasure income was $61 million primarily based on the timing of presidency procurement orders.
Smallpox income was $231 million, a rise of $30 million or 15%, reflecting deliveries beneath multiyear contracts and elevated worldwide orders. Lastly, different revenues have been $49 million. As a reminder, final 12 months’s revenues included $50 million from the Janssen settlement in addition to Camden facility income previous to its divestiture in August 2024. Normalizing for these things, different revenues grew $25 million 12 months over 12 months, as a consequence of elevated companies demand in our Winnipeg facility, together with CNG income associated to our Givanga improvement program. Turning to Slide 15, I am happy to report continued progress in strengthening our monetary place. For 2025, complete liquidity was $346 million, comprised of $246 million of money and $100 million of undrawn revolver capability.
Liquidity improved $96 million 12 months over 12 months. As of September 30, our gross debt was $693 million, down about $7 million versus the prior 12 months, pushed by our unsecured bond repurchases in the course of the quarter. Whole internet debt in Q3 2025 was $448 million, a $103 million or 19% discount. Our internet leverage remained within the 2x adjusted EBITDA vary on the finish of the third quarter, as we each elevated profitability and decreased gross debt. We additionally collected vital accounts receivable from late September MCM deliveries in early October, regardless of the present U.S. Authorities shutdown, additional enhancing our working money circulate. This consequence additional reinforces the significance of our enterprise. Please flip to Slide 16.
Our capital allocation priorities are centered on three key areas: development, debt reimbursement, and share repurchases. First, we’re investing in each natural and inorganic alternatives to strengthen our core companies and drive future income growth. Some vital tailwinds embrace rising worldwide income from our Medical Countermeasures section and our stronger steadiness sheet, which allows enterprise improvement. We stay very even handed stewards of shareholder capital and proceed to guage alternatives to advance inside R&D tasks. Subsequent, we proceed to prioritize debt reimbursement to strengthen our steadiness sheet and enhance monetary flexibility. Starting in August, we initiated a $30 million bond repurchase program and in the course of the quarter retired $6.9 million in principal quantity of unsecured bonds for $5.8 million of money.
We’re additionally dedicated to creating shareholder worth by means of the twelve-month $50 million share repurchase program we introduced in March 2025. Within the third quarter, we repurchased one other 1.1 million shares for $8.9 million, bringing us to 2.3 million repurchased 12 months thus far for $15.8 million or a mean value of $7 per share. We stay opportunistic with buybacks in future quarters as we consider market situations and different components. Transitioning to Slide 17, we’re updating our full-year 2025 steering by elevating the midpoint of our income and profitability metrics.
Additional particulars are as follows: complete revenues of $775 million to $835 million, a rise of $5 million on the midpoint; adjusted EBITDA within the vary of $195 million to $210 million, an enchancment of $15 million on the midpoint. We’re additionally elevating our adjusted gross margin steering to a spread of 52% to 54%, a 200 foundation level enchancment over our prior steering on the midpoint. On the robust efficiency 12 months thus far throughout our segments, we’re additionally elevating the midpoint of our medical countermeasures product income steering whereas sustaining our prior steering vary for industrial merchandise. Phase income steering is as follows: NCM product gross sales are $450 million to $475 million.
We proceed our enduring partnership with the U.S. Authorities, which is additional evidenced by the 11 contract modifications we have obtained 12 months thus far for our medical countermeasure merchandise. Business merchandise, together with KLXSATA, the vary of $265 million to $300 million. Yr thus far, industrial product gross sales have been $188 million with steady pricing throughout the U.S. public curiosity channel. Our efficiency in 2025 reinforces our market-leading place within the opioid overdose reversal house. In closing, on Slide 18, we’re persevering with the turnaround section of our multi-year plan with strong efficiency within the first 9 months of 2025. Our 2025 income outlook stays centered on our core enterprise throughout each the medical countermeasures and industrial segments.
Of observe, worldwide gross sales now characterize 34% of the corporate’s MCM section, which is up meaningfully from the excessive teenagers in prior years. We’re carefully monitoring this pattern and making focused investments to facilitate this development. Our partnership with the U.S. Authorities and worldwide clients stays robust, as evidenced by the 11 contract modifications 12 months thus far. Our gross margins and profitability have continued to enhance all year long, and we’re producing optimistic working money circulate whereas enhancing our liquidity place. Our leverage ratio is steady at roughly 2x adjusted EBITDA. Trying forward, our plan stays constant. We’re pursuing strategic development investments whereas actively searching for alternatives to ship worth to our shareholders.
I will now flip the decision again to Joe to debate our enterprise outlook and catalysts. Joe?
Joseph C. Papa: Thanks, Wealthy. Turning to Slide 20. Let’s start with our naloxone enterprise. Our complete Emergent group is happy with the tangible influence that Narcan has in saving many lives from opioid overdoses in the USA and Canada. Subsequent month, we’ll acknowledge the ten-year anniversary of the U.S. approval of the prescription NARCAN nasal spray. We’ll spotlight the great work that’s going to broaden entry by means of its over-the-counter availability in 2023.
And with ongoing efforts to broaden Narcan entry, added Foxado into our NARCAN DIRECT platform for ease of buying, mixed with the over $50 billion in opioid litigation settlement {dollars}, we consider that our portfolio will proceed to align with the general internet market development expectations. Shifting to slip quantity 41, I would prefer to overview the important thing outcomes from our latest Biodefense survey. There may be vital bipartisan help favoring biothreat preparedness. The underside line is that after coverage opinion leaders, the perceived danger of bioterror threats is excessive, and bioterrorism even outpaces issues about nuclear danger. It is because organic assaults are considered to be extra possible, extra imminent. These surveyed have been involved in regards to the total preparedness.
This quarter, we secured 4 new U.S. Authorities contracts price roughly $155 million mixed. We additionally efficiently secured an incremental $29 million of MCM product orders with a world authorities associate. Worldwide gross sales have been a key development driver in 2025 and characterize 34% of our MCM gross sales 12 months thus far, which is meaningfully greater than prior years. On the general public gross sales entrance, Emergent was in steady communication with our Evanga industrial associate, Ridgeback Therapeutics. Ridgeback, together with different organizations and native well being authorities, immediately supported efforts in the course of the latest Ebola outbreak within the Democratic Republic of Congo.
This outbreak, which is one in every of a number of during the last 5 years, is a stark reminder of the continued frequency and menace of the Ebola virus illness. World readiness and resilience are key to being ready for the following potential outbreak. Earlier this 12 months, we introduced our continued collaboration with BARDA to advance Evanga improvement in the direction of supplying therapy, guaranteeing we’re ready towards Ebola. On slide 22, we define our outlook on future development and money deployment. Our plan is to speculate the money we’re producing from our worthwhile enterprise segments into two development tracks. First, exploring authorities collaborations for brand spanking new biodefense merchandise.
The second is to establish value-creating exterior industrial packages that align strategically with their present enterprise mannequin and capabilities. In abstract, on slide quantity 25, we’ve got adjusted, we’ve got outperformed our top-line and adjusted EBITDA steering expectations within the third quarter. We’re elevating our full-year income steering whereas additionally elevating our adjusted EBITDA steering to $195 million to $210 million. All through 2025, our working margin and money circulate have grown considerably as we execute our multi-year turnaround plan. In conclusion, we’ve got a singular and diversified biodefense portfolio. We’re proud leaders addressing the overdose epidemic by means of our life-saving naloxone merchandise.
We’ll take extra steps to generate worth for all our stakeholders, and we’ll try for the best requirements of high quality, ethics, and compliance throughout all the Emergent enterprise. So with that, I look ahead to taking your questions. Operator, for those who please open up the road for questions.
Operator: Thanks. At the moment, we’ll conduct a query and reply session. As a reminder, to ask a query, you will want to press 11 in your phone and wait to your identify to be introduced. To withdraw your query, please press 11 once more. Our first query comes from the road of Jessica Macomber Fye from JPMorgan. The ground is yours.
Jessica Macomber Fye: Hey, guys. Good afternoon. Thanks for taking my questions. I’ve a number of. First, what drove the robust year-over-year development in different merchandise particularly? Second, with worldwide driving 34% of MCM orders 12 months thus far, can we consider these orders as recurring? Are they a part of multiyear contracts? Or are they one-off orders? And may you remind me how the gross margin on worldwide MCM orders compares to the gross margin related to US MCM gross sales? Then for Narcan, you talked about OTC gross sales and Canadian gross sales fell 12 months over 12 months. What are you seeing in every of these segments of the enterprise? And will we take into account any influence from the federal government shutdown on the NARCAN enterprise this quarter?
And what in regards to the MCM enterprise? Thanks.
Joseph C. Papa: Okay. There’s fairly a bit there, Jessica. Thanks for the questions. We should always take the primary one a part of the button beneath your class. It is there. Yeah. So a number of it’s pushed by agreements with the Evanga program having vital exercise this 12 months. And that is actually in all probability the key driver there. I feel the second query you had about our worldwide contracting and is {that a} recurring income base and multiple time. We have labored very diligently during the last eighteen months the place we made some investments in our worldwide platform to succeed in out and get extra worldwide income and gross sales. And I am glad to say that, that’s paying off and we’re seeing that.
So we view this as a part of a concentrated program and exercise. Admittedly, any given contract is for a set quantity of product in a set period of time. However we clearly see the worldwide alternative as one which can be a development alternative for us sooner or later. So in all probability one of the best reply is these merchandise are definitely a part of a selected order for a selected amount and a selected time.
However we do view this as being a world development alternative, particularly as we all know the European Union and different elements of the world are persevering with to ramp up their capabilities on this complete space of biodefense and strategic nationwide stockpile that they are organising in our workforce has been delighted to attempt to assist them as they prepare for this European Union stockpiling program on strategic nationwide measurement consciousness. Going to assist them to suppose by means of that kind of course of. On the following a part of your query, the worldwide gross margin, and one of many issues I may say is, are worldwide gross margins greater? The reply to that’s sure.
And one of many points that we’ve got is that we’ve got dedicated to the U.S. Authorities and that they’ve helped us with our funding. For our packages and our merchandise, that they’d U.S. Authorities would get what we seek advice from as most segregation pricing. So on account of that, they normally get one of the best value and different nations pay, just a little bit extra. It isn’t an enormous market distinction, however there’s a little bit higher pricing for the U.S. Authorities in that they helped us with the event of our merchandise. The subsequent query I consider was NARCIA and in Canada and what’s taking place there. We’re making good progress.
We have talked about a lot of totally different venture agreements that we’ve got with Canadian provinces and making good progress there. I might say that is one thing that is going to be variable in any given quarter when it comes to when gross sales occur within the third quarter, the fourth quarter, or subsequent 12 months. However we’re making superb progress in Canada is recognizing that they have points with opioid overdoses, they’re trying to us to assist them fulfill a few of that demand on the market. So, we’re making progress there.
There may be going to be some variability quarter over quarter when it comes to when the quarter will get shipped in third quarter, fourth quarter, or first quarter, however we’re very pleased with the connection we’ve got with the Canadian authorities. Closing query I feel you had was authorities shutdown. And I can inform you first hand, the US authorities staff that we work with on the Strategic Nationwide Stockpile of BARDA Division of Protection, proceed to work day by day they usually’re going above and past to name responsibility when it comes to what they’re doing however the shutdown.
And I can inform you first hand, Wealthy, myself, the remainder of our workforce had a gathering with the best ranges of BARDA Division of Protection, and Strategic Nationwide Stockpile simply final week. So all the things we see is a steady to maneuver ahead on these vital strategic initiatives that when it comes to what the Biodefense Constructing represents in The U.S. is vital. Should do actions. In order that they preserve working arduous and clearly there to help them any means we will. I feel I obtained all of them, Jessica, however thanks to your query. Operator, subsequent individual.
Operator: Oh, sure. Our subsequent query comes from Raghuram Selvaraju from H.C. Wainwright and Co. The ground is yours.
Eduardo Rafael Martinez-Montes: Hello, everybody. That is Eduardo on for Ram. Hoping to get just a little replace on the Rocketbats collaboration, when you’ve got any significant catalyst over the following twelve months?
Joseph C. Papa: Certain. Only a reminder for everyone. Earlier within the 12 months, we reached with Swiss Rocket, the pair Rocket Vaxx to work with them on 4 venture alternatives. They’re making good progress. On the primary product that we have acknowledged, they do have funding for the Section one in every of that. Analysis that they are now acquiring the preliminary amount of scientific trial materials. I feel that trial began. Expectation that the trial will begin someday within the early a part of 2026. And I remind you, what we consider is actually vital with the boxing bag know-how is that it’s totally different than the mRNA know-how. It’s not mRNA.
However it’s a quick to develop know-how nevertheless it makes use of stay attenuated virus know-how, vaccine know-how. And by doing that, it may very well be developed shortly, much like mRNA. Nevertheless, there’s sturdiness within the immune response as a result of they use a stay attenuated model. So that is what we’re enthusiastic about. As a result of it falls beneath one thing known as Challenge Subsequent Gen. Because the U.S. Authorities is in search of the following virus outbreak, how may it’s managed, they usually view any such know-how as being doubtlessly vital to that subsequent wave of outbreaks, no matter pandemic it is perhaps. So, sure, quickly making progress. We’re working with them.
There’s nonetheless a number of work to be doing, however they’ve the funding for the Section one beginning someday in 2026. Okay. Subsequent query.
Operator: Thanks for that query. Is there one other query you’d prefer to ask?
Eduardo Rafael Martinez-Montes: Certain. Yeah. May I get simply kinda curious extra on the NCM merchandise this time. Which of the merchandise do you suppose is gonna be the principal driver of US authorities contract-based income going ahead? And do you will have any concepts why that is perhaps?
Joseph C. Papa: Yeah. I feel the benefit that we at Emergent have is we’ve got essentially the most diversified product portfolio within the biodefense world. And all of us acknowledge that the biodefense class is we’re residing in an more and more harmful world, the know-how as we confirmed in our survey in biodefense is one thing that may very well be in a short time rolled out by some terrorists. Teams. So we predict it is vital that we’re ready. I feel it actually comes all the way down to for us, it is simply having this range of the portfolio in order that we’re prepared for any potential exercise we work very carefully with BARDA, Strategic Nationwide Stockpile, Division of Protection to make sure no matter occurs that we’re ready to assist them.
And we’re working very carefully with them. So we meet with them regularly to get ready. So I do not know if I wish to select a singular product. I feel they’re all vital to us. And I feel what’s in all probability an important factor about when you concentrate on Emergent is the variety we’ve got, whether or not it’s merchandise for smallpox, whether or not it’s a vaccine or a therapeutic merchandise for anthrax, whether or not it’s the vaccine or therapeutic merchandise for botulism. We have got throughout the tip merchandise. We’ve got all of them. And I feel that is what actually really units us other than the opposite gamers within the house.
Clearly, within the new class, we like the chance with Cimbexa. Can we see the persevering with outbreaks of Ebola? Sure, these are vital issues for us as effectively. I feel they’re going to drive an enormous a part of our future. Thanks for the query.
Operator: Thanks to your query. This concludes the query and reply session. I might now like to show it again to Joseph C. Papa, CEO, for closing remarks.
Joseph C. Papa: Nicely, thanks, everybody, for becoming a member of us at present. We very a lot recognize your curiosity in our firm. Please attain out if there’s another extra questions. However we’re enthusiastic about what Emergent is carrying out this 12 months. I feel we’re effectively on our strategy to have one other good 12 months for us and one other nice quarter. And really a lot due to all working at Emergent for all of the work they’ve executed to assist us have a really robust 12 months thus far. Thanks, everybody, for becoming a member of us at present. Have an excellent day.
Operator: Thanks to your participation in at present’s convention. This does conclude this system. You could now disconnect.
Ever really feel such as you missed the boat in shopping for essentially the most profitable shares? You then’ll wish to hear this.
On uncommon events, our knowledgeable workforce of analysts points a “Double Down” inventory advice for corporations that they suppose are about to pop. For those who’re apprehensive you’ve already missed your likelihood to speculate, now’s one of the best time to purchase earlier than it’s too late. And the numbers communicate for themselves:
-
Nvidia: for those who invested $1,000 once we doubled down in 2009, you’d have $536,975!*
-
Apple: for those who invested $1,000 once we doubled down in 2008, you’d have $51,258!*
-
Netflix: for those who invested $1,000 once we doubled down in 2004, you’d have $593,442!*
Proper now, we’re issuing “Double Down” alerts for 3 unbelievable corporations, accessible if you be part of Inventory Advisor, and there might not be one other likelihood like this anytime quickly.
*Inventory Advisor returns as of October 27, 2025
This text is a transcript of this convention name produced for The Motley Idiot. Whereas we try for our Silly Greatest, there could also be errors, omissions, or inaccuracies on this transcript. As with all our articles, The Motley Idiot doesn’t assume any accountability to your use of this content material, and we strongly encourage you to do your personal analysis, together with listening to the decision your self and studying the corporate’s SEC filings. Please see our Phrases and Circumstances for added particulars, together with our Compulsory Capitalized Disclaimers of Legal responsibility.
The Motley Idiot recommends Emergent BioSolutions. The Motley Idiot has a disclosure coverage.
Emergent BioSolutions (EBS) Earnings Transcript was initially revealed by The Motley Idiot
